Table of Content

1. Executive Summary
1.1. Global Bile Duct Cancer Treatment Market Snapshot, 2025 and 2032
1.2. Market Opportunity Assessment, 2025 – 2032, US$ Bn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Macro-Economic Factors
2.3.1. Global Sectorial Outlook
2.3.2. Global GDP Growth Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors – Relevance and Impact
3. Value Added Insights
3.1. Regulatory Landscape
3.2. Product Adoption Analysis
3.3. Value Chain Analysis
3.4. Key Deals and Mergers
3.5. PESTLE Analysis
3.6. Porter’s Five Force Analysis
4. Global Bile Duct Cancer Treatment Market Outlook:
4.1. Key Highlights
4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Bn) Analysis and Forecast
4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2023
4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025–2032
4.3. Global Bile Duct Cancer Treatment Market Outlook: Treatment Type
4.3.1. Introduction / Key Findings
4.3.2. Historical Market Size (US$ Bn) Analysis, By Treatment Type, 2019 – 2023
4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment Type, 2025 – 2032
4.3.3.1. Chemotherapy
4.3.3.1.1. Gemcitabine-based
4.3.3.1.2. Cisplatin-based
4.3.3.1.3. Combination therapies
4.3.3.1.4. Others
4.3.3.2. Targeted Therapy
4.3.3.2.1. Epidermal Growth Factor Receptor (EGFR) inhibitors
4.3.3.2.2. Vascular Endothelial Growth Factor (VEGF) inhibitors
4.3.3.2.3. Others
4.3.3.3. Radiation Therapy
4.3.3.4. Immunotherapy
4.3.3.5. Surgery
4.3.3.6. Others
4.3.4. Market Attractiveness Analysis: Treatment Type
4.4. Global Bile Duct Cancer Treatment Market Outlook: Disease Type
4.4.1. Introduction / Key Findings
4.4.2. Historical Market Size (US$ Bn) Analysis, By Disease Type, 2019 – 2023
4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Type, 2025 – 2032
4.4.3.1. Intrahepatic Cholangiocarcinoma
4.4.3.2. Extrahepatic Cholangiocarcinoma
4.4.3.2.1. Perihilar Cholangiocarcinoma (Klatskin tumors)
4.4.3.2.2. Distal Cholangiocarcinoma
4.4.4. Market Attractiveness Analysis: Disease Type
4.5. Global Bile Duct Cancer Treatment Market Outlook: Distribution Channel
4.5.1. Introduction / Key Findings
4.5.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019 – 2023
4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025 – 2032
4.5.3.1. Hospital Pharmacies
4.5.3.2. Retail Pharmacies
4.5.3.3. Online Pharmacies
4.5.4. Market Attractiveness Analysis: Distribution Channel
5. Global Bile Duct Cancer Treatment Market Outlook: Region
5.1. Key Highlights
5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019 – 2023
5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025 – 2032
5.3.1. North America
5.3.2. Europe
5.3.3. East Asia
5.3.4. South Asia and Oceania
5.3.5. Latin America
5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region
6. North America Bile Duct Cancer Treatment Market Outlook:
6.1. Key Highlights
6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 – 2023
6.2.1. By Country
6.2.2. By Treatment Type
6.2.3. By Disease Type
6.2.4. By Distribution Channel
6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 – 2032
6.3.1. U.S.
6.3.2. Canada
6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment Type, 2025 – 2032
6.4.1. Chemotherapy
6.4.1.1. Gemcitabine-based
6.4.1.2. Cisplatin-based
6.4.1.3. Combination therapies
6.4.1.4. Others
6.4.2. Targeted Therapy
6.4.2.1. Epidermal Growth Factor Receptor (EGFR) inhibitors
6.4.2.2. Vascular Endothelial Growth Factor (VEGF) inhibitors
6.4.2.3. Others
6.4.3. Radiation Therapy
6.4.4. Immunotherapy
6.4.5. Surgery
6.4.6. Others
6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Type, 2025 – 2032
6.5.1. Intrahepatic Cholangiocarcinoma
6.5.2. Extrahepatic Cholangiocarcinoma
6.5.2.1. Perihilar Cholangiocarcinoma (Klatskin tumors)
6.5.2.2. Distal Cholangiocarcinoma
6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025 – 2032
6.6.1. Hospital Pharmacies
6.6.2. Retail Pharmacies
6.6.3. Online Pharmacies
6.7. Market Attractiveness Analysis
7. Europe Bile Duct Cancer Treatment Market Outlook:
7.1. Key Highlights
7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 – 2023
7.2.1. By Country
7.2.2. By Treatment Type
7.2.3. By Disease Type
7.2.4. By Distribution Channel
7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 – 2032
7.3.1. Germany
7.3.2. France
7.3.3. U.K.
7.3.4. Italy
7.3.5. Spain
7.3.6. Russia
7.3.7. Türkiye
7.3.8. Rest of Europe
7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment Type, 2025 – 2032
7.4.1. Chemotherapy
7.4.1.1. Gemcitabine-based
7.4.1.2. Cisplatin-based
7.4.1.3. Combination therapies
7.4.1.4. Others
7.4.2. Targeted Therapy
7.4.2.1. Epidermal Growth Factor Receptor (EGFR) inhibitors
7.4.2.2. Vascular Endothelial Growth Factor (VEGF) inhibitors
7.4.2.3. Others
7.4.3. Radiation Therapy
7.4.4. Immunotherapy
7.4.5. Surgery
7.4.6. Others
7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Type, 2025 – 2032
7.5.1. Intrahepatic Cholangiocarcinoma
7.5.2. Extrahepatic Cholangiocarcinoma
7.5.2.1. Perihilar Cholangiocarcinoma (Klatskin tumors)
7.5.2.2. Distal Cholangiocarcinoma
7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025 – 2032
7.6.1. Hospital Pharmacies
7.6.2. Retail Pharmacies
7.6.3. Online Pharmacies
7.7. Market Attractiveness Analysis
8. East Asia Bile Duct Cancer Treatment Market Outlook:
8.1. Key Highlights
8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 – 2023
8.2.1. By Country
8.2.2. By Treatment Type
8.2.3. By Disease Type
8.2.4. By Distribution Channel
8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 – 2032
8.3.1. China
8.3.2. Japan
8.3.3. South Korea
8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment Type, 2025 – 2032
8.4.1. Chemotherapy
8.4.1.1. Gemcitabine-based
8.4.1.2. Cisplatin-based
8.4.1.3. Combination therapies
8.4.1.4. Others
8.4.2. Targeted Therapy
8.4.2.1. Epidermal Growth Factor Receptor (EGFR) inhibitors
8.4.2.2. Vascular Endothelial Growth Factor (VEGF) inhibitors
8.4.2.3. Others
8.4.3. Radiation Therapy
8.4.4. Immunotherapy
8.4.5. Surgery
8.4.6. Others
8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Type, 2025 – 2032
8.5.1. Intrahepatic Cholangiocarcinoma
8.5.2. Extrahepatic Cholangiocarcinoma
8.5.2.1. Perihilar Cholangiocarcinoma (Klatskin tumors)
8.5.2.2. Distal Cholangiocarcinoma
8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025 – 2032
8.6.1. Hospital Pharmacies
8.6.2. Retail Pharmacies
8.6.3. Online Pharmacies
8.7. Market Attractiveness Analysis
9. South Asia & Oceania Bile Duct Cancer Treatment Market Outlook:
9.1. Key Highlights
9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 – 2023
9.2.1. By Country
9.2.2. By Treatment Type
9.2.3. By Disease Type
9.2.4. By Distribution Channel
9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 – 2032
9.3.1. India
9.3.2. Southeast Asia
9.3.3. ANZ
9.3.4. Rest of South Asia & Oceania
9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment Type, 2025 – 2032
9.4.1. Chemotherapy
9.4.1.1. Gemcitabine-based
9.4.1.2. Cisplatin-based
9.4.1.3. Combination therapies
9.4.1.4. Others
9.4.2. Targeted Therapy
9.4.2.1. Epidermal Growth Factor Receptor (EGFR) inhibitors
9.4.2.2. Vascular Endothelial Growth Factor (VEGF) inhibitors
9.4.2.3. Others
9.4.3. Radiation Therapy
9.4.4. Immunotherapy
9.4.5. Surgery
9.4.6. Others
9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Type, 2025 – 2032
9.5.1. Intrahepatic Cholangiocarcinoma
9.5.2. Extrahepatic Cholangiocarcinoma
9.5.2.1. Perihilar Cholangiocarcinoma (Klatskin tumors)
9.5.2.2. Distal Cholangiocarcinoma
9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025 – 2032
9.6.1. Hospital Pharmacies
9.6.2. Retail Pharmacies
9.6.3. Online Pharmacies
9.7. Market Attractiveness Analysis
10. Latin America Bile Duct Cancer Treatment Market Outlook:
10.1. Key Highlights
10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 – 2023
10.2.1. By Country
10.2.2. By Treatment Type
10.2.3. By Disease Type
10.2.4. By Distribution Channel
10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 – 2032
10.3.1. Brazil
10.3.2. Mexico
10.3.3. Rest of Latin America
10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment Type, 2025 – 2032
10.4.1. Chemotherapy
10.4.1.1. Gemcitabine-based
10.4.1.2. Cisplatin-based
10.4.1.3. Combination therapies
10.4.1.4. Others
10.4.2. Targeted Therapy
10.4.2.1. Epidermal Growth Factor Receptor (EGFR) inhibitors
10.4.2.2. Vascular Endothelial Growth Factor (VEGF) inhibitors
10.4.2.3. Others
10.4.3. Radiation Therapy
10.4.4. Immunotherapy
10.4.5. Surgery
10.4.6. Others
10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Type, 2025 – 2032
10.5.1. Intrahepatic Cholangiocarcinoma
10.5.2. Extrahepatic Cholangiocarcinoma
10.5.2.1. Perihilar Cholangiocarcinoma (Klatskin tumors)
10.5.2.2. Distal Cholangiocarcinoma
10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025 – 2032
10.6.1. Hospital Pharmacies
10.6.2. Retail Pharmacies
10.6.3. Online Pharmacies
10.7. Market Attractiveness Analysis
11. Middle East & Africa Bile Duct Cancer Treatment Market Outlook:
11.1. Key Highlights
11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 – 2023
11.2.1. By Country
11.2.2. By Treatment Type
11.2.3. By Disease Type
11.2.4. By Distribution Channel
11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 – 2032
11.3.1. GCC Countries
11.3.2. Egypt
11.3.3. South Africa
11.3.4. Northern Africa
11.3.5. Rest of Middle East & Africa
11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Treatment Type, 2025 – 2032
11.4.1. Chemotherapy
11.4.1.1. Gemcitabine-based
11.4.1.2. Cisplatin-based
11.4.1.3. Combination therapies
11.4.1.4. Others
11.4.2. Targeted Therapy
11.4.2.1. Epidermal Growth Factor Receptor (EGFR) inhibitors
11.4.2.2. Vascular Endothelial Growth Factor (VEGF) inhibitors
11.4.2.3. Others
11.4.3. Radiation Therapy
11.4.4. Immunotherapy
11.4.5. Surgery
11.4.6. Others
11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Type, 2025 – 2032
11.5.1. Intrahepatic Cholangiocarcinoma
11.5.2. Extrahepatic Cholangiocarcinoma
11.5.2.1. Perihilar Cholangiocarcinoma (Klatskin tumors)
11.5.2.2. Distal Cholangiocarcinoma
11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025 – 2032
11.6.1. Hospital Pharmacies
11.6.2. Retail Pharmacies
11.6.3. Online Pharmacies
11.7. Market Attractiveness Analysis
12. Competition Landscape
12.1. Market Share Analysis, 2025
12.2. Market Structure
12.2.1. Competition Intensity Mapping By Market
12.2.2. Competition Dashboard
12.3. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
12.3.1. Pfizer, Inc.
12.3.1.1. Overview
12.3.1.2. Segments and Products
12.3.1.3. Key Financials
12.3.1.4. Market Developments
12.3.1.5. Market Strategy
12.3.2. F. Hoffmann-La Roche AG
12.3.3. Bristol-Myers Squibb Company
12.3.4. Teva Pharmaceuticals Industries Ltd.
12.3.5. Eli Lilly and Company
12.3.6. Novartis AG
12.3.7. Sanofi
12.3.8. Fresenius Kabi AG
12.3.9. Mylan N.V.
12.3.10. Kyowa Hakko Kirin Co Ltd.
12.3.11. Intercept Pharmaceuticals, Inc.
12.3.12. Accord Healthcare Inc.
12.3.13. Delcath Systems Inc.
12.3.14. Celgene Corporation
12.3.15. Johnson & Johnson
12.3.16. Others
13. Appendix
13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations